Bellevue, WA - October 24, 2024 The Binaytara Foundation, a leading global cancer non-profit organization dedicated to improving access to…
ESMO 2023 Update - KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author:…
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung…
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng,…
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III…
On October 11, 2023, the U.S. Food and Drug Administration granted approval to Encorafenib (BRAF inhibitor) with Binimetinib (MEK inhibitor)…
Author: Saramshika Dhakal, MBBS Tribhuvan University Teaching Hospital, Kathmandu, Nepal. In a recent article published in JAMA Oncology (JAMA…
On September 26, the U.S. Food and Drug Administration expanded the approval of bosutinib (Bosulif) to include pediatric patients 1…
Presented by: Chris Chen, MD, Director, Early Drug Development, Stanford Cancer Institute Covered by: Inas Abuali, MD, FACP Dr. Chris…
On August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with…